PropertyValue
?:abstract
  • Johnson & Johnson says it has identified a lead vaccine candidate for the new coronavirus that it will develop in partnership with the US Biomedical Advanced Research and Development Authority (BARDA) J&J began developing the vaccine in January, as soon as the virus’s sequence became available The firm says it and BARDA are willing to spend more than $1 billion to get the adenoviral vaccine into human clinical studies by September and available for emergency use in early 2021
?:creator
?:journal
  • C&EN_Global_Enterprise
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • J&J, BARDA advance coronavirus vaccine
?:type
?:who_covidence_id
  • #35169
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/qz8epwq2>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/qz8epwq2>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all